video thumbnail

Pancreatic Cancer Finally Cured in Mice | Groundbreaking Spanish Study

Duration: 29:00

Published On Apr 23, 2026

Write A New Comment

0 Comments

Targeted Triple Inhibition of KRAS, EGFR, and STAT3 in Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by near-universal activating mutations in KRAS and frequent co-mutations in TP53, CDKN2A, and SMAD4. Despite advances in targeted therapy, single-agent inhibition of KRAS has demonstrated limited durability due to rapid emergence of adaptive resistance mechanisms.

This lecture reviews a recent preclinical study demonstrating that simultaneous pharmacologic inhibition of three critical signaling nodes—KRAS, EGFR, and STAT3—induces complete and durable tumor regression in murine models of PDAC, including orthotopic and patient-derived xenograft (PDX) systems.

By the end of this lecture, participants will be able to:
* Explain why KRAS-mutant PDAC demonstrates rapid resistance to single-agent KRAS inhibition.
* Describe the role of EGFR and STAT3 in adaptive signaling escape.
* Discuss this study curing PDX in mice by blocking STAT3 protein clusters.
* Evaluate the strengths and limitations of preclinical combination therapy studies.

By the end of this lecture, participants will be able to:
* Explain why KRAS-mutant PDAC demonstrates rapid resistance to single-agent KRAS inhibition.
* Describe the role of EGFR and STAT3 in adaptive signaling escape.
* Discuss this study curing PDX in mice by blocking STAT3 protein clusters.
* Evaluate the strengths and limitations of preclinical combination therapy studies.

Following answers are created by ChatGPT. Occasionally the answer may be harmful, incorrect, false, misleading, incomplete, or limited in knowledge of world. Please contact your doctor for all healthcare decisions. Also, double check the answer provided by the AI below.

Faculty

In addition to the presenter, following authors may have helped with the content writing, review, or approval:

CME, CE, CEU and Other Credit Types:

ACCME Accreditation Statement
The DrBeen Corp is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The DrBeen Corp designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Disclosure Information

In accordance with the disclosure policies of DrBeen Corp and the ACCME (Accreditation Council for Continuing Medical Education), we are committed to upholding principles of balance, independence, objectivity, and scientific rigor in all of our Continuing Medical Education (CME) and Continuing Education (CE) activities. These policies include the careful management and mitigation of any relevant financial relationships with organizations that are not eligible.
All members of the Activity Planning Committee and presenters have disclosed their relevant financial relationships. The DrBeen Corp CE Committee has thoroughly reviewed these disclosures and determined that these relationships are not deemed inappropriate in the context of their respective presentations. Additionally, they are found to be consistent with the educational objectives and the integrity of the activity.

Faculty Disclosures

Please login to access this content.

Don't have an account?

See Plans

Instructors

Pharma Mastery

Related Videos